1. Diagnosis, management and prevention ofCandida aurisin hospitals: position statement of the Australasian Society for Infectious Diseases
- Author
-
Rita Roy, Chong W. Ong, Catriona Halliday, Christopher H. Heath, Andrew J. Stewardson, Julia E Clark, Leon J Worth, Monica A. Slavin, Caroline Marshall, Deborah Marriott, Arthur J. Morris, Sarah E. Kidd, C. Orla Morrissey, and Sharon C.-A. Chen
- Subjects
medicine.medical_specialty ,Antifungal Agents ,Antifungal drug ,Microbial Sensitivity Tests ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Drug Resistance, Fungal ,Amphotericin B ,Amphotericin B deoxycholate ,Disease Transmission, Infectious ,Internal Medicine ,Humans ,Medicine ,Infection control ,030212 general & internal medicine ,DNA, Fungal ,Intensive care medicine ,Fluconazole ,Societies, Medical ,Candida ,Cross Infection ,Infection Control ,business.industry ,Age Factors ,Australia ,Candidiasis ,Outbreak ,Candida auris ,Diagnosis management ,business ,New Zealand ,medicine.drug - Abstract
Candida auris is an emerging drug-resistant yeast responsible for hospital outbreaks. This statement reviews the evidence regarding diagnosis, treatment and prevention of this organism and provides consensus recommendations for clinicians and microbiologists in Australia and New Zealand. C. auris has been isolated in over 30 countries (including Australia). Bloodstream infections are the most frequently reported infections. Infections have crude mortality of 30-60%. Acquisition is generally healthcare-associated and risks include underlying chronic disease, immunocompromise and presence of indwelling medical devices. C. auris may be misidentified by conventional phenotypic methods. Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry or sequencing of the internal transcribed spacer regions and/or the D1/D2 regions of the 28S ribosomal DNA are therefore required for definitive laboratory identification. Antifungal drug resistance, particularly to fluconazole, is common, with variable resistance to amphotericin B and echinocandins. Echinocandins are currently recommended as first-line therapy for infection in adults and children ≥2 months of age. For neonates and infants
- Published
- 2019